Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Irene Ganan-Gomez; Hui Yang; Feiyang Ma; Guillermo Montalban-Bravo; Natthakan Thongon; Valentina Marchica; Guillaume Richard-Carpentier; Kelly Chien; Ganiraju Manyam; Feng Wang; Ana Alfonso; Shuaitong Chen; Caleb Class; Rashmi Kanagal-Shamanna; Justin P. Ingram; Yamini Ogoti; Ashley Rose; Sanam Loghavi; Pamela Lockyer; Benedetta Cambo; Muharrem Muftuoglu; Sarah Schneider; Vera Adema; Michael McLellan; John Garza; Matteo Marchesini; Nicola Giuliani; Matteo Pellegrini; Jing Wang; Jason Walker; Ziyi Li; Koichi Takahashi; Joel D. Leverson; Carlos Bueso-Ramos; Michael Andreeff; Karen Clise-Dwyer; Guillermo Garcia-Manero; Simona Colla

doi:10.1038/s41591-022-01827-x

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Irene Ganan-Gomez
, Hui Yang
, Feiyang Ma
, Guillermo Montalban-Bravo
, Natthakan Thongon
, Valentina Marchica
, Guillaume Richard-Carpentier
, Kelly Chien
, Ganiraju Manyam
, Feng Wang
, Ana Alfonso
, Shuaitong Chen
, Caleb Class
, Rashmi Kanagal-Shamanna
, Justin P. Ingram
, Yamini Ogoti
, Ashley Rose
, Sanam Loghavi
, Pamela Lockyer
, Benedetta Cambo

Muharrem Muftuoglu, Sarah Schneider, Vera Adema, Michael McLellan, John Garza, Matteo Marchesini, Nicola Giuliani, Matteo Pellegrini, Jing Wang, Jason Walker, Ziyi Li, Koichi Takahashi, Joel D. Leverson, Carlos Bueso-Ramos, Michael Andreeff, Karen Clise-Dwyer, Guillermo Garcia-Manero, Simona Colla

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

Original language	English (US)
Pages (from-to)	1097
Number of pages	1
Journal	Nature medicine
Volume	28
Issue number	5
DOIs	https://doi.org/10.1038/s41591-022-01827-x
State	Published - May 2022

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

MD Anderson CCSG core facilities

Biostatistics Resource Group
Bioinformatics Shared Resource
Flow Cytometry and Cellular Imaging Facility

Access to Document

10.1038/s41591-022-01827-x

Fingerprint

Dive into the research topics of 'Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)'. Together they form a unique fingerprint.

Cite this

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., Marchica, V., Richard-Carpentier, G., Chien, K., Manyam, G., Wang, F., Alfonso, A., Chen, S., Class, C., Kanagal-Shamanna, R., Ingram, J. P., Ogoti, Y., Rose, A., Loghavi, S., Lockyer, P., ... Colla, S. (2022). Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4). Nature medicine, 28(5), 1097. https://doi.org/10.1038/s41591-022-01827-x

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4). / Ganan-Gomez, Irene; Yang, Hui; Ma, Feiyang et al.
In: Nature medicine, Vol. 28, No. 5, 05.2022, p. 1097.

Research output: Contribution to journal › Comment/debate › peer-review

Ganan-Gomez, I, Yang, H, Ma, F, Montalban-Bravo, G , Thongon, N, Marchica, V, Richard-Carpentier, G, Chien, K, Manyam, G, Wang, F, Alfonso, A, Chen, S, Class, C, Kanagal-Shamanna, R, Ingram, JP, Ogoti, Y, Rose, A, Loghavi, S, Lockyer, P, Cambo, B, Muftuoglu, M, Schneider, S, Adema, V, McLellan, M, Garza, J, Marchesini, M, Giuliani, N, Pellegrini, M, Wang, J, Walker, J, Li, Z , Takahashi, K, Leverson, JD, Bueso-Ramos, C , Andreeff, M, Clise-Dwyer, K, Garcia-Manero, G & Colla, S 2022, 'Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)', Nature medicine, vol. 28, no. 5, pp. 1097. https://doi.org/10.1038/s41591-022-01827-x

@article{ded03a0af50e43b38d1ff99cabd4a872,

title = "Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)",

abstract = "In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.",

author = "Irene Ganan-Gomez and Hui Yang and Feiyang Ma and Guillermo Montalban-Bravo and Natthakan Thongon and Valentina Marchica and Guillaume Richard-Carpentier and Kelly Chien and Ganiraju Manyam and Feng Wang and Ana Alfonso and Shuaitong Chen and Caleb Class and Rashmi Kanagal-Shamanna and Ingram, \{Justin P.\} and Yamini Ogoti and Ashley Rose and Sanam Loghavi and Pamela Lockyer and Benedetta Cambo and Muharrem Muftuoglu and Sarah Schneider and Vera Adema and Michael McLellan and John Garza and Matteo Marchesini and Nicola Giuliani and Matteo Pellegrini and Jing Wang and Jason Walker and Ziyi Li and Koichi Takahashi and Leverson, \{Joel D.\} and Carlos Bueso-Ramos and Michael Andreeff and Karen Clise-Dwyer and Guillermo Garcia-Manero and Simona Colla",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = may,

doi = "10.1038/s41591-022-01827-x",

language = "English (US)",

volume = "28",

pages = "1097",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "5",

}

TY - JOUR

T1 - Author Correction

T2 - Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

AU - Ganan-Gomez, Irene

AU - Yang, Hui

AU - Ma, Feiyang

AU - Montalban-Bravo, Guillermo

AU - Thongon, Natthakan

AU - Marchica, Valentina

AU - Richard-Carpentier, Guillaume

AU - Chien, Kelly

AU - Manyam, Ganiraju

AU - Wang, Feng

AU - Alfonso, Ana

AU - Chen, Shuaitong

AU - Class, Caleb

AU - Kanagal-Shamanna, Rashmi

AU - Ingram, Justin P.

AU - Ogoti, Yamini

AU - Rose, Ashley

AU - Loghavi, Sanam

AU - Lockyer, Pamela

AU - Cambo, Benedetta

AU - Muftuoglu, Muharrem

AU - Schneider, Sarah

AU - Adema, Vera

AU - McLellan, Michael

AU - Garza, John

AU - Marchesini, Matteo

AU - Giuliani, Nicola

AU - Pellegrini, Matteo

AU - Wang, Jing

AU - Walker, Jason

AU - Li, Ziyi

AU - Takahashi, Koichi

AU - Leverson, Joel D.

AU - Bueso-Ramos, Carlos

AU - Andreeff, Michael

AU - Clise-Dwyer, Karen

AU - Garcia-Manero, Guillermo

AU - Colla, Simona

PY - 2022/5

Y1 - 2022/5

N2 - In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

AB - In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

UR - https://www.scopus.com/pages/publications/85128977272

UR - https://www.scopus.com/pages/publications/85128977272#tab=citedBy

U2 - 10.1038/s41591-022-01827-x

DO - 10.1038/s41591-022-01827-x

M3 - Comment/debate

C2 - 35484266

AN - SCOPUS:85128977272

SN - 1078-8956

VL - 28

SP - 1097

JO - Nature medicine

JF - Nature medicine

IS - 5

ER -

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this